Role of secretory phospholipase A₂ in women with metabolic syndrome

D. Pop¹², A. Sitar-Tăut¹³, G. Bodisz², D. Zdrenghea¹², M. Cebanu¹ & L. Stanca³

¹University of Medicine & Pharmacy, Department of Internal Medicine, ²Rehabilitation Hospital, Discipline of Cardiology, Department of Internal Medicine & ³Babes-Bolyai University, Faculty of Economics & Business Administration, Department of Economic Informatics, Cluj-Napoca, Romania

Received February 15, 2012

Background & objectives: Secretory phospholipase A₂ (sPLA₂), a member of the phospholipase A2 superfamily of enzymes that hydrolyses phospholipids, is a potentially useful plasma biomarker for atherosclerotic cardiovascular disease. Cardiovascular diseases are the leading cause of mortality in women. The purpose of this study was to investigate the correlation between cardiovascular risk factors and the sPLA₂ levels in women with metabolic syndrome as compared to women without metabolic syndrome and men with metabolic syndrome.

Methods: Patients (n=100) with various cardiovascular risk factors consecutively evaluated at the Rehabilitation Hospital-Cardiology Department, Cluj-Napoca, Romania were enrolled during 2011, of whom 10 were excluded. The patients were divided in three groups: group 1 (37 women with metabolic syndrome), group 2 (27 men with metabolic syndrome), and group 3 (26 women without metabolic syndrome). Body weight, smoking habits, glycaemia, hypertension, and serum lipids fractions were analysed as cardiovascular factors. Serum sPLA₂ activity was measured using the chromogenic method.

Results: There were no statistically significant correlations between sPLA₂ levels and the investigated risk factors, irrespective of patient groups. However, there were significant positive correlations between sPLA₂ and hsCRP in all three groups (P<0.05). In women with no metabolic syndrome an negative correlation was found between sPLA₂ levels and HDL-C- r=0.419, P=0.03. In men with metabolic syndrome there was a direct correlation between sPLA₂ levels and HOMA, r=0.43, P<0.05, 95% CI (-0.098; 1.15).

Interpretation & conclusions: Women with metabolic syndrome did not display different sPLA₂ levels as compared to men with metabolic syndrome and women without metabolic syndrome. However, women with metabolic syndrome demonstrated a low but positive correlation between sPLA₂ and hsCRP levels.

Key words Cardiovascular risk factors - metabolic syndrome - sPLA₂
Cardiovascular diseases are the leading cause of death in women\(^1\); in Europe almost 55 per cent of mortality in women is caused by cardiovascular diseases, chiefly coronary disease and stroke\(^2\). In this context, the present research takes into special consideration the novel markers of cardiovascular risk\(^3\), under the circumstances in which cardiovascular risk factors and charts downplay cardiovascular risk in women. Moreover, endothelial dysfunction and inflammation play a major role in the pathogenesis of microvascular angina, common among women\(^4\). The respective markers may be divided into three categories: inflammation, haemostasis, and other factors. It is well known that lipoprotein (a) is highly atherothrombotic, and its elevated levels increase the risk of cardiovascular disease\(^5\) and represent an independent risk factor for coronary disease\(^6\). The lipoprotein (a) is shown to be correlated to the progression, extension, and severity of the coronary disease, as well as to a negative prognostic after myocardial infarction\(^6\). There is evidence that its levels increase with age in women\(^6\). Elevated levels in women indicate an independent atherogenetic risk factor both in pre- and postmenopausal women\(^7\). It has been shown that high lipoprotein levels in women are associated with an increasing risk of cerebrovascular accident (CVA)\(^8\). There are studies which show that secretory phospholipase A\(_2\) (sPLA\(_2\)) levels are more elevated in women than in men, along with an increase in C-reactive protein (CRP) levels\(^9\).

There is evidence that the sPLA\(_2\) hydrolyses phospholipids, generating free fatty acids and lisa phospholipidases, which lead to an increase of proinflammatory factors in the arterial wall\(^10\). These have a chemotactic and oxidative effect on the smooth muscular arterial cells and on the monocytes/macrophages. sPLA\(_2\) also determines the generation of platelet-activating factor (PAF), with proatherogenic and procoagulant role\(^10\).

The present study was undertaken to find out the relationship between sPLA\(_2\) levels and cardiovascular risk factors in women with metabolic syndrome (MS) and compare with women without MS and men with MS.

**Material & Methods**

A total of 100 patients with various cardiovascular risk factors consecutively evaluated at the Rehabilitation Hospital-Cardiology Department, Cluj-Napoca, Romania, were in retrospectively included in the study, of whom 10 were excluded because some of the laboratory parameters were not determined accurately. Patients with ischaemic heart disease were also excluded. They were divided in three groups: group 1 (37 women with metabolic syndrome), group 2 (27 men with metabolic syndrome), and group 3 (26 women without metabolic syndrome). The study was carried out in 2011. As cardiovascular risk factors body weight, smoking habits, glycaemia, hypertension, serum lipids fractions and high sensitivity C-reactive protein (hsCRP) were analysed. Blood pressure was measured according to standard protocol as the mean of two readings after the participant was at rest for 5 min in a sitting position. The metabolic syndrome was defined according to the criteria of the International Diabetes Federation\(^11\). Body mass index (BMI) (kg/m\(^2\)) was derived from height and weight measured in the clinic with participants wearing light clothing and no shoes. Blood samples (10 ml) were obtained by venipuncture according to the standard Lipid Research Clinics Protocol\(^12\). Low-density lipoprotein cholesterol (LDL-C) was estimated using the Friedewald formula\(^13\). The homeostasis model assessment (HOMA-IR) was used to estimate insulin resistance [(HOMA-IR (Insulin resistance) (mmol/LxμU/ml) = fasting glucose (mmol/l) X fasting insulin (μU/ml)/405]. Plasma glucose levels were measured by the glucose oxidase method\(^14\). The hsCRP was analyzed by chemiluminescent immunometric assay (IMMULITE 2000)\(^15\). sPLA\(_2\) levels were measured by Cayman’s secretory PLA\(_2\) (sPLA\(_2\)) assay kit (Cayman Chemical Company, Ann Arbor MI, USA). The detection range of the assay was from 0.02 to 0.2 μU/min/ml of sPLA activity, which was equivalent to an absorbance increase of 0.01 to 0.1/min.

Arterial stiffness (pulse wave velocity) was measured using TensioMedTMArteriograph (KFT, Hungary). The study protocol was approved by the ethics committee of University of Medicine and Pharmacy, Cluj-Napoca, Romania.

**Statistical analysis:** Microsoft Excel 2007 (v.6.0: Microsoft Corporation, Redmond, WA), Epinfo 2000 (v.6.0, EpInfo Development team CDC, GA, Atlanta) and SPSS 13 (v.13.0; IBM Corporation, Armonk, NY, USA) for Windows were used for data analysis. The data were presented as mean ± 1 SD or percentages when appropriate. First, the data normality was tested by applying the Kolmogorov-Smirnov test. Then, in agreement with the results, either Levene’s test for equality of variances or Bartlett’s chi square test was applied. In the former case, the results led to the application of the independent samples t test-equivalent.
variances. In Bartlett’s chi square test, Mann-Whitney (Wilcoxon Rank Sum) or the Student t-test was applied. In the case of dichotomous variables, depending on the context, either Fisher or chi-square test was applied.

**Results**

Male patients with metabolic syndrome displayed a significantly elevated glycaemia than women with MS ($P<0.01$). On the contrary, women without MS had higher levels of total cholesterol and LDL-C ($P=0.01$, $P<0.05$). HDL-C was also more elevated in women with MS, ($P<0.01$) (Table).

In the remaining cardiovascular risk factors, there were no significant differences between the sexes. There were no significant differences in sPLA$_2$ levels among between the three groups of patients (Table).

To assess whether there were correlations between cardiovascular risk factors, and sPLA$_2$, the analyses were done. In general, there were no significant correlations between the sPLA$_2$ levels and either of the studied risk factors, irrespective of the group of patients under examination. However, in women with metabolic syndrome there was a low positive correlation ($r=0.141$, $P<0.05$) between sPLA$_2$ levels and hsCRP (Fig. 1). But the same correlation appeared to be present in women with no metabolic syndrome also (Spearman coefficient rho=-0.243, $P<0.05$). A significant correlation between sPLA$_2$ and hsCRP was also found in men with metabolic syndrome ($r=-0.39$, $P<0.05$) (Fig. 2). At the same time, the female patients without metabolic syndrome displayed a significantly inverse correlation between sPLA$_2$ and HDL-C- $r=-0.419$, $P<0.05$ (Fig. 3). In men with metabolic syndrome there was a direct relationship between sPLA$_2$ and HOMA, $r=0.43$, $P<0.05$) (Fig. 4).

**Discussion**

Traditional risk factors can predict the risk of cardiovascular disease in many, but not in all, patients. About 10 to 20 per cent patients with coronary heart disease display no identifiable risk factor$^{16}$. Many studies have established that lipoprotein associated phospholipase A2 (Lp-PLA2) is a cardiovascular marker independent of but correlated and augmentative to established risk factors$^{17}$. Lp-PLA2 is produced by the inflammatory cells involved in atherogenesis and is accumulated in atherosclerotic lesions. It is well known that about 70 - 80 per cent of the Lp-PLA2 circulates in blood bound to LDL, and the rest to Lp(a), HDL cholesterol, and a very small quantity to VLDL$^{18}$.

| Variable          | Females with metabolic syndrome (n=37) | Females without metabolic syndrome (n=26) | Males with metabolic syndrome (n=27) |
|-------------------|---------------------------------------|------------------------------------------|-----------------------------------|
| Age (yr)          | 57.46 ± 10.73                         | 53 ± 10.40                               | 61.41 ± 9.82                      |
| Smokers (%)       | 10.81*                                | 30.76                                    | 22.22**                           |
| BMI (kg/m$^2$)    | 29.54 ± 4.02*                         | 26.17 ± 4.43                             | 30.57 ± 3.91                      |
| Glycaemia (mg/dl) | 100.68 ± 16.2***                      | 86.15 ± 9.65                             | 113.67 ± 26.70*                   |
| HOMA              | 2.23 ± 2.01**                         | 1.16 ± 0.73                              | 2.30 ± 1.08                       |
| Total C (mg/dl)   | 221.24 ± 41.85                        | 225.88 ± 9.65                            | 192.93 ± 46.0**                   |
| LDL-C (mg/dl)     | 141.14 ± 34.38                        | 150.42 ± 24.77                           | 115.78 ± 35.30++                  |
| HDL-C (mg/dl)     | 44.95 ± 6.78***                       | 51 ± 7.37                                | 38.89 ± 10.60++                   |
| TG (mg/dl)        | 175.89 ± 83.21*                       | 118.62 ± 49.17                           | 195.52 ± 82.13++                  |
| Hypertension (%)  | 72.97*                                | 38.5                                     | 85.18                             |
| Diabetes (%)      | 27.02                                 | -                                        | 33.33                             |
| hsCRP (mg/dl)     | 3.43 ± 3.52                           | 2.84 ± 4.54                              | 4.29 ± 4.93                       |
| PWV Ao (m/sec)    | 9.98 ± 2.01                           | 10.52 ± 2.71                             | 10.57 ± 1.82                      |
| sPLA2 (μmol/min/ml)| 5.69 ± 1.41                           | 5.44 ± 1.0                               | 5.63 ± 1.33                       |

BMI, Body mass index; Total C, total cholesterol; LDL-C, LDL cholesterol; HDL-C, HDL cholesterol; TG, triglycerides; hsCRP, high sensitivity C reactive protein; PWV Ao, pulse wave velocity on aorta; sPLA2, secretory phospholipase A2

* $P<0.05$, ** $<0.01$, *** $<0.001$ compared with women without metabolic syndrome

$P<0.05$, ** $<0.01$ compared with women with metabolic syndrome

---

868  INDIAN J MED RES, DECEMBER 2013
Fig. 1. Correlation between sPLA$_2$ ($\mu$mol/min/ml) and hsCRP (mg/dl) in women with metabolic syndrome.

Fig. 2. Correlation between sPLA$_2$ ($\mu$mol/min/ml) and hsCRP (mg/dl) in men with metabolic syndrome.

Fig. 3. Correlation between sPLA$_2$ ($\mu$mol/min/ml) and HDL-C (mg/dl) in women without metabolic syndrome.
Secretory phospholipase A2 (sPLA2), a member of the phospholipase A2 superfamily of enzymes, is a potentially useful plasma biomarker for atherosclerotic cardiovascular disease. The 2010 ACCF/AHA (American College of Cardiology Foundation / American Heart Association) Guideline for Assessment of Cardiovascular Risk in Asymptomatic Adults\textsuperscript{19} recommends that Lp-PLA2 might be reasonable for cardiovascular risk assessment in intermediate-risk asymptomatic adults (IIbB). Gong \textit{et al.}\textsuperscript{20} found increased plasma levels of Lp-PLA2 in patients with metabolic syndrome.

There are five major classes of PLA2: the secreted and cytosolic forms, the calcium-independent PLA2s, the lysosomal PLA2s and the platelet-activating factor acetylhydrolases (PAF-AH, which include Lp-PLA2 and are also calcium independent)\textsuperscript{10}. sPLA2 is also involved in atherogenesis in several ways: it changes the affinity of LDL particles for extracellular matrix proteins\textsuperscript{21-23}, with their accumulation in the arterial walls, favours lipid peroxidation\textsuperscript{24} and mediates the hydrolysis of certain lysophospholipids and free fatty acids\textsuperscript{25}. Circulating levels of sPLA2 are higher in patients with documented CAD than in controls\textsuperscript{26}.

We found an inverse correlation between sPLA2 levels and HDL cholesterol levels in women without metabolic syndrome. An increase in HDL-C levels has been shown to be accompanied by a decline in the levels of inflammatory factors\textsuperscript{27}. An increase in the sPLA2 activity determines the hydrolysis of HDL-C particles both within and without the context of inflammatory processes\textsuperscript{28,29}. sPLA2 may determine changes in the HDL-C levels that can eventually upset the beneficial mechanisms involved in the macrophage cholesterol efflux\textsuperscript{29}.

An association was seen between sPLA2 and CRP levels, which represents both acute-phase proteins and markers of vascular inflammation, in patients with and without metabolic syndrome. Koenig \textit{et al.}\textsuperscript{30} also found a significant direct correlation between the levels of sPLA2 type IIA and CRP. Another study conducted in patients with insulin resistance, documented correlations between sPLA2 and CRP, as well as interleukin (IL)-6 and soluble adhesion molecules\textsuperscript{31}. The question arises whether sPLA2 also plays a part in the pathogenesis of metabolic syndrome. Ravaux \textit{et al.}\textsuperscript{32} have shown that the ligands of all three peroxisome proliferator activated receptors (PPARs) in the vascular smooth muscle may determine a decrease in the sPLA2 expression. Results from UDACS study demonstrated that in patients with type 2 diabetes mellitus, changes in the \textit{PLA2G2A} genes might alter sPLA\textsubscript{2} levels\textsuperscript{33}.

Pulse wave velocity on aorta (PWV\textsubscript{Ao}) is deemed to be an investigation that may contribute in assessing individual cardiovascular risk, but is still not used on a large scale. No significant correlation was recorded between sPLA\textsubscript{2} and PWV\textsubscript{Ao} in the present study. Men with metabolic syndrome showed higher values of both sPLA\textsubscript{2} and PWV\textsubscript{Ao} than women with MS.

In conclusion, women with metabolic syndrome did not display different sPLA\textsubscript{2} values as compared to men with metabolic syndrome and women without metabolic syndrome, irrespective of traditional cardiovascular
Acknowledgment

This study was conducted within the framework of Research Project No. 947, ID_2246/ 2009 Code, part of PN II Program funded by the Romanian Ministry of Education, Research and Innovation-The National University Research Council.

References

1. Mosca L, Benjamin EJ, Berra K, Benzsonz JL, Dolor RJ, Lloyd-Jones DM, et al. Effectiveness-Based guidelines for the prevention of cardiovascular disease in women - 2011 update. Circulation 2011; 123 : 1243-62.

2. Stramba-Badiale M, Fox KM, Priori SG, Collins P, Daly C, Graham I, et al. Cardiovascular diseases in women: a statement from the policy conference of the European Society of Cardiology. Eur Heart J 2006; 27 : 994-1005.

3. Kim HC, Greenland P, Rossouw JE, Manson JE, Cochrane BB, Lasser NL, et al. Multimarker Prediction of Coronary Heart Disease Risk: The Women’s Health Initiative. J Am Coll Cardiol 2010; 55 : 2080-91.

4. Newby KI, Douglas PS. Cardiovascular disease in women. In: Bonow RO, Mann DL, Zipes DP, Libby P, editors. Heart Disease - A textbook of cardiovascular medicine. 5th ed. Philadelphia: Elsevier; 2011; p. 1757-69.

5. Pilote L, Dasgupta K, Guru V, Humphries K, McGrath J, Norris C, et al. A comprehensive view of sex-specific issues related to cardiovascular disease. CMAJ 2007; 176 : S1-41.

6. Herald K, Koskinen S, Jouslahti P, Torppa J, Vartiainen E, Salomaa V. Changes in traditional risk factors no longer explain time trends in cardiovascular mortality and its socioeconomic differences. J Epidemiol Community Health 2008; 62 : 251-7.

7. Stangl V, Baumann G, Stangl K Coronary atherogenic risk factors in women. Eur Heart J 2002; 23 : 1738-52.

8. Wassertheil-Smoller S, Kooperberg C, McGinn AP, Kaplan RC, Hsia J, Hendrix SL, et al. Lipoprotein-associated phospholipase A2, hormone use, and the risk of ischemic stroke in postmenopausal women. Hypertension 2008; 51 : 1115-22.

9. Rana JS, Cote M, Després JP, Sandhu MS, Talmud PJ, Ninio E, et al. Inflammatory biomarkers and the prediction of coronary events among people at intermediate risk: the EPIC-Norfolk Prospective Population Study. Heart 2009; 95 : 1682.

10. Suckling K. Phospholipase A2s: Developing drug targets for atherosclerosis. Atherosclerosis 2010; 2 : 357-66.

11. Tong PC, Kong AP, So WY, Yang X, Ho CS, Ma RC, et al. The usefulness of the International Diabetes Federation and the National Cholesterol Education Program’s Adult Treatment Panel III definitions of the metabolic syndrome in predicting coronary heart disease in subjects with type 2 diabetes. Diabetes Care 2007; 30 : 1206-11.

12. The Lipid Research Clinics Coronary Primary Prevention Trial Results I. Reduction in Incidence of Coronary Heart Disease. JAMA 1984; 251 : 351-64.

13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative centrifuge. Clin Chem 1972; 18 : 499-500.

14. Lott JA, Turner K. Evaluation of Trinder’s glucose oxidase method for measuring glucose in serum and urine. Clin Chem 1975; 21 : 1754-60.

15. Available from: http://usa.healthcare.siemens.com/clinical-specialities/cardiology/cardiovascular-disease/educational-content/hscrp, accessed on November 1, 2013.

16. Khot UN, Khot MB, Bajzer CT, Sapp SK, Ohman EM, Brener SJ, et al. Prevalence of conventional risk factors in patients with coronary heart disease. JAMA 2003; 290 : 898-904.

17. Garza CA, Montori VM, McConnell JP, Somers VK, Kullo JJ, Lopez-Jimenez F. Association between lipoprotein-associated phospholipase A2 and cardiovascular disease: a systematic review. Mayo Clin Proc 2007; 82 : 159-65.

18. Nambi V, Ballantyne CM. Lipoprotein-associated phospholipase A2: pathogenic mechanism and clinical utility for predicting cardiovascular events. Curr Atheroscler Rep 2006; 8 : 374-81.

19. Greenland P, Alpert JS, Beller GA, Benjamin EJ, Budoff MJ, Fayad ZA, et al; American College of Cardiology Foundation; American Heart Association. 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. J Am Coll Cardiol 2010; 56 : e50-103.

20. Gong HP, Du YM, Zhong LN, Dong ZQ, Wang X, Yao YJ, et al. Plasma lipoprotein-associated phospholipase A2 in patients with metabolic syndrome and carotid atherosclerosis. Lipids Health Dis 2011; 10 : 10:13.

21. Camego G, Hurt-Camego E, Wikklund O, Bondjers G. Association of apo B lipoproteins with arterial proteoglycans: pathological significance and molecular basis. Atherosclerosis 1998; 139 : 205-22.

22. Sartipy P, Camego G, Svensson L, Hurt-Camego E. Phospholipase A2(2) modification of low density lipoproteins forms small high density particles with increased affinity for proteoglycans and glycosaminoglycans. J Biol Chem 1999; 274 : 25913-20.

23. Hakala JK, Oorni K, Pentikainen MO, Hurt-Camego E, Kovanen PT. Lipolysis of LDL by human secretory phospholipase A(2) induces particle fusion and enhances the retention of LDL to human aortic proteoglycans. Arterioscler Thromb Vasc Biol 2001; 21 : 1053-8.

24. Neuzil J, Upston JM, Witting PK, Scott KF, Stocker R. Secretory phospholipase A2 and lipoprotein lipase enhance 15-lipoxygenase-induced enzymic and nonenzymic lipid peroxidation in low-density lipoproteins. Biochemistry 1998; 37 : 9203-10.

25. Oestvang J, Bonnefont-Rousselot D, Ninio E, Hakala JK, Johansen B, Anthonsen MW. Modification of LDL with human secretory phospholipase A2 or sphingomyelinase promotes its arachidonic acid-releasing propensity. J Lipid Res 2004; 45 : 831-8.

26. Liu PY, Li YH, Tsai WC, Chao TH, Tsai LM, Wu HL, et al. Prognostic value and the changes of plasma levels of secretory
type II phospholipase A2 in patients with coronary artery disease undergoing percutaneous coronary intervention. *Eur Heart J* 2003; 24:1824-32.

27. Wadham C, Albanese N, Roberts J, Wang L, Bagley CJ, Gamble JR, et al. High-density lipoproteins neutralize C-reactive protein proinflammatory activity. *Circulation* 2004; 109: 2116-22.

28. Pruzanski W, Stefanski E, de Beer FC, de Beer MC, Vadas P, Ravandi A, et al. Lipoproteins are substrates for human secretory group IIA phospholipase A2: preferential hydrolysis of acute phase HDL. *J Lipid Res* 1998; 39: 2150-60.

29. Tietge UJ, Maugeais C, Cain W, Grass D, Glick JM, de Beer FC, et al. Overexpression of secretory phospholipase A2 causes rapid catabolism and altered tissue uptake of high density lipoprotein cholesteryl ester and apolipoprotein A-I. *J Biol Chem* 2000; 275: 10077-84.

30. Koenig W, Vossen CY, Mallat Z, Brenner H, Benessiano J, Rothenbacher D. Association between type II secretory phospholipase A2 plasma concentrations and activity and cardiovascular events in patients with coronary heart disease. *Eur Heart J* 2009; 30: 2742-8.

31. Gora S, Lambeau G, Bollinger JG, Gelb M, Ninio E, Karabina SA. The proinflammatory mediator platelet activating factor is an effective substrate for human group X secreted phospholipase A2. *Biomed Biochem Acta* 2006; 1761: 1093-9.

32. Ravaux L, Denoyelle C, Monne C, Limon I, Raymondjean M, El Hadri K. Inhibition of interleukin-1beta-induced group IIA secretory phospholipase A2 expression by peroxisome proliferator-activated receptors (PPARs) in rat vascular smooth muscle cells: cooperation between PPARbeta and the proto-oncogene BCL-6. *Mol Cell Biol* 2007; 27: 8374-87.

33. Wotton P, Drenos F, Cooper J, Thompson SR, Stephens JW, Hurt-Camejo E, et al. Tagging-SNP haplotype analysis of the secretory PLA2IIa gene PLA2G2A shows strong association with serum levels of sPLA2-IIa: results from the UDACS study. *Hum Mol Genet* 2006; 15: 355-61.

Reprint requests: Dr Pop Dana, Bihorului 5 Str, Cluj-Napoca, Romania
e-mail: pop7dana@yahoo.com, liana_stanca@yahoo.com